甲基2,3-二基酸盐通过通过IPA和HSC70向调节自和炎症来改善AD小鼠的认知功能
Opeyemi B Fasina1, Lanjie Li1, Danni Chen1
1College of Pharmaceutical Science, Zhejiang University, 866 Yu Hang Road, Hangzhou 310058, China.
International journal of molecular sciences
|November 9, 2024
概括
甲基2,3-二基酸盐 (ABG-001) 通过促进神经发生和激活自,有效治疗阿尔茨海默病 (AD). 这种化合物也对肠道微生物群产生积极影响,产生-3-酸 (IPA),其向Hsc70以改善记忆功能障碍.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
背景情况:
- 阿尔茨海默病 (AD) 的发病过程复杂,使药物开发具有挑战性.
- 甲基2,3-二基酸盐 (ABG-001) 具有NGF模仿和抗衰老特性,显示出治疗潜力.
- 现有的AD治疗因疾病复杂性而面临局限性.
研究的目的:
- 在高脂肪饮食 (HFD) 诱导和自然衰老的AD小鼠模型中评估ABG-001的抗AD作用.
- 确定分子标并阐明ABG-001.1.的作用机制.
- 探索肠道微生物群调节在ABG-001治疗疗效中的作用.
主要方法:
- 使用HFD诱导和自然衰老的AD小鼠模型.
- 采用了转录组学 (RNA-seq),蛋白质组学 (西方涂抹,ELISA,CETSA,DARTS) 和成像学 (免疫光学).
- 进行SPR分析,基因表达研究,以及用于肠道微生物群分析的16SrRNA测序.
主要成果:
- 在AD小鼠模型中,ABG-001显著缓解了两个AD小鼠模型中的记忆缺陷.
- 治疗效果与增强的神经发生,激活伴侣介导自 (CMA) 和减少神经炎症有关.
- ABG-001调节了肠道微生物群,增加了英多尔-3-酸 (IPA) 的产生,该酸向热冲击相关的70kDa蛋白 (Hsc70).
结论:
- ABG-001在阿尔茨海默病中显示出显著的治疗潜力.
- 该机制涉及IPA介导的针对Hsc70,调节关键信号通路 (Hsc70/PKM2/HK2/LC3和FOXO3a/SIRT1).
- 调节肠道微生物群和采用抗衰老策略,为神经退行性疾病提供了一个新的治疗途径.
相关概念视频
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
98
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
98


